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Sir,
The KRAS mutations in colorectal cancer (CRC) are associated
with clinical resistance to treatment with the epidermal growth
factor receptor – targeted monoclonal antibodies. The clinical
confirmation of these findings in independent retrospective
reports as well as in a phase III trial has led the European
Medicines Agency (August 2008) to license panitumumab and
cetuximab only for patients with CRC without KRAS mutations
(http://www.emea.europa.eu/humandocs/Humans/EPAR/erbitux/
erbitux.htm and http://www.emea.europa.eu/humandocs/Humans/
EPAR/vectibix/vectibix.htm). In the European Public Assessment
Report, the natures of the KRAS mutations were described as
‘certain hot-spots (mainly codons 12 and 13)’.
The most recent clinical studies report seven somatic mutations
in these two codons 12–13 (Amado et al, 2008; Lievre et al, 2008).
They use either direct sequencing (Lievre et al, 2008), which
addresses few codons surrounding codons 12–13 or focus
techniques like Scorpion-ARM (Amado et al, 2008), which detects
only mutations on codons 12–13 with a high sensitivity.
From March 2008, our genomic platform has tested 70 CRC
patients for KRAS status. Using a pre-screening approach in
codons 12–13 with high-resolution melting curve analysis (Simi
et al, 2008) followed by sequencing, we found 35% cases with a
mutation in codons 12–13, in agreement with the literature.
However, we also report two cases presenting a mutation in codon
19 (c.57G4C, p.Leu19Phe), without mutations in codons 12–13.
No polymorphism has been reported in this codon (dbSNP –
http://www.ncbi.nlm.nih.gov/SNP/). In the two cases, the intensity
of the mutated allele in the sequence electropherogram was under
30% of the normal allele. With a heterozygous polymorphism, the
intensity between mutated and normal allele should have been
similar.
A functional study reported a similar mutation (c.57G4T,
p.Leu19Phe) as an activating mutation with proliferative
consequences (Akagi et al, 2007). In the large Netherlands Cohort
Study (n¼737 CRC), 37% mutations were found in codons 12–13
and 6.6% were found outside codons 12–13, in codons 8, 9, 10, 15,
16, 19, 20 or 25 (Brink et al, 2003). A recent report in a Polish
population stressed also the finding of mutations in codons 59, 61,
117 in 163 CRC (Wojcik et al, 2008). Those mutations cannot be
detected with focus techniques. None of those mutations were
quoted either in the recent clinical reports assessing the sensitivity
to treatment (Amado et al, 2008; Lievre et al, 2008), or in the
Scientific Discussion at the EMEA.
Most clinical studies limited the test to KRAS codons 12–13, but
additional KRAS-activating mutations could be considered in the
choice of the treatment. In France, 36000 new cases of CRC have
been estimated each year, leading to potentially 800 patients
harbouring false wild-type KRAS status and which would not
respond to targeted treatments. Activating mutations in codons
other than 12–13 raise the question of a precise definition of KRAS
mutation status in a routine laboratory and clinical practice.
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